{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:40:20Z","timestamp":1790516420853,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,12]]},"abstract":"<jats:p>Comparison of the pharmacokinetics (PK) of a coagulation factor between groups of patients can be biased by differences in study protocols, in particular between blood sampling schedules. This could affect clinical dose tailoring, especially in children. The aim of this study was to describe the relationships of the PK of factor VIII (FVIII) with age and body weight by a population PK model. The potential to reduce blood sampling was also explored. A model was built for FVIII PK from 236 infusions of recombinant FVIII in 152 patients (1-65 years of age) with severe hemophilia A. The PK of FVIII over the entire age range was well described by a 2-compartment model and a previously reported problem, resulting from differences in blood sampling, to compare findings from children and adults was practically abolished. The decline in FVIII clearance and increase in half-life with age could be described as continuous functions. Retrospective reduction of blood sampling from 11 to 5 samples made no important difference to the estimates of PK parameters. The obtained findings can be used as a basis for PK-based dose tailoring of FVIII in clinical practice, in all age groups, with minimal blood sampling.<\/jats:p>","DOI":"10.1182\/blood-2011-07-360594","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:38:35Z","timestamp":1320107915000},"page":"612-618","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":185,"title":["Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight"],"prefix":"10.1182","volume":"119","author":[{"given":"Sven","family":"Bj\u00f6rkman","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MyungShin","family":"Oh","sequence":"additional","affiliation":[{"name":"Baxter Healthcare Corporation, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Spotts","sequence":"additional","affiliation":[{"name":"Baxter Healthcare Corporation, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Schroth","sequence":"additional","affiliation":[{"name":"Baxter Healthcare Corporation, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandor","family":"Fritsch","sequence":"additional","affiliation":[{"name":"Baxter Innovations GmbH, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Ewenstein","sequence":"additional","affiliation":[{"name":"Baxter Healthcare Corporation, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Casey","sequence":"additional","affiliation":[{"name":"Baxter Healthcare Corporation, Westlake Village, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathelijn","family":"Fischer","sequence":"additional","affiliation":[{"name":"Van Creveldkliniek & Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S.","family":"Blanchette","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology, Hospital for Sick Children, and Department of Paediatrics, University of Toronto, Toronto, ON; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Collins","sequence":"additional","affiliation":[{"name":"Arthur Bloom Haemophilia Centre, Department of Haematology, Medical School of Cardiff University, University Hospital of Wales, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111818382955200_B1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens.","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111818382955200_B2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"issue":"3","key":"2019111818382955200_B3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jcp.35.3.289","article-title":"Effect of height and weight on the in vivo recovery of transfused factor VIII C.","volume":"35","author":"Aronstam","year":"1982","journal-title":"J Clin Pathol"},{"issue":"1","key":"2019111818382955200_B4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0609.1985.tb00739.x","article-title":"Kinetic evaluation of four factor VIII concentrates by model-independent methods.","volume":"34","author":"Matucci","year":"1985","journal-title":"Scand J Haematol"},{"issue":"5","key":"2019111818382955200_B5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-199222050-00005","article-title":"Pharmacokinetics of factor VIII in humans: obtaining clinically relevant data from comparative studies.","volume":"22","author":"Bj\u00f6rkman","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2019111818382955200_B6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2516.1997.00091.x","article-title":"Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.","volume":"3","author":"Carlsson","year":"1997","journal-title":"Haemophilia"},{"issue":"11","key":"2019111818382955200_B7","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00003088-200140110-00003","article-title":"Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.","volume":"40","author":"Bj\u00f6rkman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2019111818382955200_B8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.9.s1.4.x","article-title":"Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.","volume":"9","author":"Bj\u00f6rkman","year":"2003","journal-title":"Haemophilia"},{"issue":"4","key":"2019111818382955200_B9","first-page":"494","article-title":"Factor VIII half-life and clinical phenotype of severe hemophilia A.","volume":"90","author":"van Dijk","year":"2005","journal-title":"Haematologica"},{"key":"2019111818382955200_B10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2516.2006.01333.x","article-title":"Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of inter-patient pharmacokinetic variability.","volume":"12","author":"Barnes","year":"2006","journal-title":"Haemophilia"},{"issue":"8","key":"2019111818382955200_B11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1538-7836.2008.03032.x","article-title":"Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.","volume":"6","author":"Blanchette","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2019111818382955200_B12","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range of 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.","volume":"65","author":"Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2019111818382955200_B13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1538-7836.2010.03757.x","article-title":"Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.","volume":"8","author":"Bj\u00f6rkman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111818382955200_B14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/03602538409015063","article-title":"The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.","volume":"15","author":"Sheiner","year":"1984","journal-title":"Drug Metab Rev"},{"issue":"6","key":"2019111818382955200_B15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2125.1991.tb03971.x","article-title":"Population pharmacokinetics: theory and practice.","volume":"32","author":"Aarons","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"2019111818382955200_B16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2516.2006.01334.x","article-title":"Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII: an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia.","volume":"12","author":"Stass","year":"2006","journal-title":"Haemophilia"},{"issue":"1","key":"2019111818382955200_B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/FTD.0b013e3180311384","article-title":"A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.","volume":"29","author":"Bolon-Larger","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"4","key":"2019111818382955200_B18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A.","volume":"16","author":"Bj\u00f6rkman","year":"2010","journal-title":"Haemophilia"},{"issue":"1","key":"2019111818382955200_B19","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/j.1365-2516.2010.02372.x","article-title":"Evaluation of the TCIWorks Bayes-ian computer program for estimation of individual pharmacokinetics of FVIII.","volume":"17","author":"Bj\u00f6rkman","year":"2011","journal-title":"Haemophilia"},{"issue":"5","key":"2019111818382955200_B20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2516.2004.00932.x","article-title":"Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma\/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.","volume":"10","author":"Tarantino","year":"2004","journal-title":"Haemophilia"},{"issue":"6","key":"2019111818382955200_B21","first-page":"745","article-title":"A two-phase linear regression model for biologic half-life data.","volume":"115","author":"Lee","year":"1990","journal-title":"J Lab Clin Med"},{"key":"2019111818382955200_B22","unstructured":"Lee M Morfini M Schulman S The design and analysis of pharmacokinetic studies of coagulation factors. Accessed July 24, 2009 http:\/\/www.isth.org\/Publications\/OfficialCommunications\/Factor8and9\/Pharmacokinetic.asp"},{"issue":"6","key":"2019111818382955200_B23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses.","volume":"21","author":"Karlsson","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"2019111818382955200_B24","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1208\/aapsj070248","article-title":"Population pharmacokinetic studies in pediatrics: issues in design and analysis.","volume":"7","author":"Meibohm","year":"2005","journal-title":"AAPS J"},{"issue":"6","key":"2019111818382955200_B25","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003088-199222060-00004","article-title":"Bayesian parameter estimation and population pharmacokinetics.","volume":"22","author":"Thomson","year":"1992","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2019111818382955200_B26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10928-005-0062-y","article-title":"Non-linear mixed effects modeling: from methodology and software development to driving implementation in drug development science.","volume":"32","author":"Pillai","year":"2005","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2019111818382955200_B27","unstructured":"Food and Drug Administration Guidance for industry: population pharmacokinetics. Accessed March 17, 2011 http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072137.pdf"},{"issue":"11","key":"2019111818382955200_B28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00228-009-0699-3","article-title":"Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients.","volume":"65","author":"Karafoulidou","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2019111818382955200_B29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","article-title":"A size standard for pharmacokinetics.","volume":"30","author":"Holford","year":"1996","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2019111818382955200_B30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2006.01401.x","article-title":"In vivo recovery of factor VIII and factor IX: intra- and inter-individual variance in a clinical setting.","volume":"13","author":"Bj\u00f6rkman","year":"2007","journal-title":"Haemophilia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/2\/612\/1497777\/zh800212000612.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/2\/612\/1497777\/zh800212000612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T04:05:27Z","timestamp":1713067527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/2\/612\/105521\/Population-pharmacokinetics-of-recombinant-factor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-07-360594","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}